---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-025393"
form_type: "8-K"
ticker: "NEPH"
cik: "0001196298"
company_name: "NEPHROS INC"
filed_at: "2022-09-08T23:59:59+00:00"
generated_at: "2026-06-23T12:34:45.970310+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Nephros appoints Joe Harris to Board of Directors, effective September 6, 2022

## Summary
- Joe Harris appointed as Class III Director, term expiring at 2023 Annual Meeting.
- Harris will serve on Audit and Compensation Committees.
- Standard non-employee director compensation: $20,000 annual retainer, $1,500 per board meeting.
- Granted option to purchase 13,115 shares at $1.25/share, vesting over 3 years.
- Harris brings 20+ years sales management experience; currently Midwest Sales Director at Murj.

## SEC filing metadata
- accession: 0001493152-22-025393
- form_type: 8-K
- ticker: NEPH
- cik: 0001196298
- company_name: NEPHROS INC
- filed_at: 2022-09-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1196298/000149315222025393/0001493152-22-025393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1196298/000149315222025393/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-025393
- JSON: https://secwatch.observer/filing/0001493152-22-025393.json
- Plain text: https://secwatch.observer/filing/0001493152-22-025393.txt

## Key facts
- Executive change
  Joseph Harris was appointed as Class III Director at NEPHROS INC.
  - Action: appointed
  - Role: Class III Director
  source text: appointed Joseph Harris as a director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1196298/000149315222025393/0001493152-22-025393-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.